Clinical Pharmacology‐Informed Development of COVID‐19 Therapeutics: Regulatory Experience-Reference-Cited by-同舟云学术

Clinical Pharmacology‐Informed Development of COVID‐19 Therapeutics: Regulatory Experience

Published:2021-03-14 Issue:4 Volume:109 Page:810-812
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Choi Su‐Young¹,Arya Vikram¹,Reynolds Kellie¹

Affiliation:

1. Division of Infectious Disease Pharmacology Office of Clinical Pharmacology Office of Translational Sciences Center for Drug Evaluation and Research US Food and Drug Administration Silver Spring Maryland USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2210

Reference9 articles.

1. . Accessed September 24 2020.

2. Dose Rationale for Favipiravir Use in Patients Infected With SARS‐CoV‐2

3. Toward consensus on correct interpretation of protein binding in plasma and other biological matrices for COVID‐19 therapeutic development;Boffito M.;Clin. Pharmacol. Ther.,2021

4. A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics

5. Completion Rate and Reporting of Mandatory Pediatric Postmarketing Studies Under the US Pediatric Research Equity Act

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An Open Label, Adaptive, Phase 1 Trial of High‐Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS‐CoV‐2;Clinical Pharmacology & Therapeutics;2021-11-13

2. The Complex Roadmap to Infectious Disease Innovation: The Intersection of Bugs, Drugs, and Special Populations;Clinical Pharmacology & Therapeutics;2021-03-26